World Journal of Diabetes最新文献

{"title":"Association between sensitivity to thyroid hormones and non-high-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus.","authors":"Xiao-Ye Duan, Jun-Ling Fu, Li-Na Sun, Zhi-Jing Mu, Shuang-Ling Xiu","doi":"10.4239/wjd.v15.i10.2081","DOIUrl":"10.4239/wjd.v15.i10.2081","url":null,"abstract":"<p><strong>Background: </strong>Dyslipidemia and type 2 diabetes mellitus (T2DM) are chronic conditions with substantial public health implications. Effective management of lipid metabolism in patients with T2DM is critical. However, there has been insufficient attention given to the relationship between thyroid hormone sensitivity and dyslipidemia in the T2DM population, particularly concerning non-high-density lipoprotein cholesterol (non-HDL-C).</p><p><strong>Aim: </strong>To clarify the association between thyroid hormone sensitivity and dyslipidemia in patients with T2DM.</p><p><strong>Methods: </strong>In this cross-sectional study, thyroid hormone sensitivity indices, the thyroid feedback quantile-based index (TFQI), the thyroid-stimulating hormone index (TSHI), the thyrotrophic T4 resistance index (TT4RI), and the free triiodothyronine (FT3)/free thyroxine (FT4) ratio were calculated. Logistic regression analysis was performed to determine the associations between those composite indices and non-HDL-C levels. Random forest variable importance and Shapley Additive Explanations (SHAP) summary plots were used to identify the strength and direction of the association between hyper-non-HDL-C and its major predictor.</p><p><strong>Results: </strong>Among the 994 participants, 389 (39.13%) had high non-HDL-C levels. Logistic regression analysis revealed that the risk of hyper-non-HDL-C was positively correlated with the TFQI (OR: 1.584; 95%CI: 1.088-2.304; <i>P</i> = 0.016), TSHI (OR: 1.238; 95%CI: 1.034-1.482; <i>P</i> = 0.02), and TT4RI (OR: 1.075; 95%CI: 1.006-1.149; <i>P</i> = 0.032) but was not significantly correlated with the FT3/FT4 ratio. The relationships between composite indices of the thyroid system and non-HDL-C levels differed according to sex. An increased risk of hyper-non-HDL-C was associated with elevated TSHI levels in men (OR: 1.331; 95%CI: 1.003-1.766; <i>P</i> = 0.048) but elevated TFQI levels in women (OR: 2.337; 95%CI: 1.4-3.901; <i>P</i> = 0.001). Among the analyzed variables, the average SHAP values were highest for TSHI, followed by TT4RI.</p><p><strong>Conclusion: </strong>Impaired sensitivity to thyroid hormones was associated with high non-HDL-C levels in patients with T2DM.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"15 10","pages":"2081-2092"},"PeriodicalIF":4.2,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of immune feature genes and intercellular profiles in diabetic cardiomyopathy.","authors":"Ze-Qun Zheng, Di-Hui Cai, Yong-Fei Song","doi":"10.4239/wjd.v15.i10.2093","DOIUrl":"10.4239/wjd.v15.i10.2093","url":null,"abstract":"<p><strong>Background: </strong>Diabetic cardiomyopathy (DCM) is a multifaceted cardiovascular disorder in which immune dysregulation plays a pivotal role. The immunological molecular mechanisms underlying DCM are poorly understood.</p><p><strong>Aim: </strong>To examine the immunological molecular mechanisms of DCM and construct diagnostic and prognostic models of DCM based on immune feature genes (IFGs).</p><p><strong>Methods: </strong>Weighted gene co-expression network analysis along with machine learning methods were employed to pinpoint IFGs within bulk RNA sequencing (RNA-seq) datasets. Single-sample gene set enrichment analysis (ssGSEA) facilitated the analysis of immune cell infiltration. Diagnostic and prognostic models for these IFGs were developed and assessed in a validation cohort. Gene expression in the DCM cell model was confirmed through real time-quantitative polymerase chain reaction and western blotting techniques. Additionally, single-cell RNA-seq data provided deeper insights into cellular profiles and interactions.</p><p><strong>Results: </strong>The overlap between 69 differentially expressed genes in the DCM-associated module and 2483 immune genes yielded 7 differentially expressed immune-related genes. Four IFGs showed good diagnostic and prognostic values in the validation cohort: Proenkephalin (Penk) and retinol binding protein 7 (Rbp7), which were highly expressed, and glucagon receptor and inhibin subunit alpha, which were expressed at low levels in DCM patients (all area under the curves > 0.9). SsGSEA revealed that IFG-related immune cell infiltration primarily involved type 2 T helper cells. High expression of Penk (<i>P</i> < 0.0001) and Rbp7 (<i>P</i> = 0.001) was detected in cardiomyocytes and interstitial cells and further confirmed in a DCM cell model <i>in vitro</i>. Intercellular events and communication analysis revealed abnormal cellular phenotype transformation and signaling communication in DCM, especially between mesenchymal cells and macrophages.</p><p><strong>Conclusion: </strong>The present study identified Penk and Rbp7 as potential DCM biomarkers, and aberrant mesenchymal-immune cell phenotype communication may be an important aspect of DCM pathogenesis.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"15 10","pages":"2093-2110"},"PeriodicalIF":4.2,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delayed treatment of diabetic foot ulcer in patients with type 2 diabetes and its prediction model.","authors":"Hui Chen, Ying Xi","doi":"10.4239/wjd.v15.i10.2070","DOIUrl":"10.4239/wjd.v15.i10.2070","url":null,"abstract":"<p><strong>Background: </strong>Diabetic foot (DF) is a serious complication of type 2 diabetes. This study aimed to investigate the factors associated with DF occurrence and the role of delayed medical care in a cohort of patients with type 2 diabetes.</p><p><strong>Aim: </strong>To reveal the impact of delayed medical treatment on the development of DF in patients with type 2 diabetes and to establish a predictive model for DF.</p><p><strong>Methods: </strong>In this retrospective cohort study, 292 patients with type 2 diabetes who underwent examination at our hospital from January 2023 to December 2023 were selected and divided into the DF group (<i>n</i> = 82, DF) and nondiabetic foot group (<i>n</i> = 210, NDF). Differential and correlation analyses of demographic indicators, laboratory parameters, and delayed medical treatment were conducted for the two groups. Logistic regression was applied to determine influencing factors. Receiver operating characteristic (ROC) analysis was performed, and indicators with good predictive value were selected to establish a combined predictive model.</p><p><strong>Results: </strong>The DF group had significantly higher body mass index (BMI) (<i>P</i> < 0.001), disease duration (<i>P</i> = 0.012), plasma glucose levels (<i>P</i> < 0.001), and HbA1c (<i>P</i> < 0.001) than the NDF group. The NDF group had significantly higher Acute Thrombosis and Myocardial Infarction Health Service System (ATMHSS) scores (<i>P</i> < 0.001) and a significantly lower delayed medical treatment rate (72.38% <i>vs</i> 13.41%, <i>P</i> < 0.001). BMI, duration of diabetes, plasma glucose levels, HbA1c, diabetic peripheral neuropathy, and nephropathy were all positively correlated with DF occurrence. ATMHSS scores were negatively correlated with delayed time to seek medical treatment. The logistic regression model revealed that BMI, duration of diabetes, plasma glucose levels, HbA1c, presence of diabetic peripheral neuropathy and nephropathy, ATMHSS scores, and delayed time to seek medical treatment were influencing factors for DF. ROC analysis indicated that plasma glucose levels, HbA1c, and delayed medical treatment had good predictive value with an area under the curve of 0.933 for the combined predictive model.</p><p><strong>Conclusion: </strong>Delayed medical treatment significantly affects the probability of DF occurrence in patients with diabetes. Plasma glucose levels, HbA1c levels, and the combined predictive model of delayed medical treatment demonstrate good predictive value.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"15 10","pages":"2070-2080"},"PeriodicalIF":4.2,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions.","authors":"Jing-Jing Zhu, John P H Wilding, Xiao-Song Gu","doi":"10.4239/wjd.v15.i10.2135","DOIUrl":"10.4239/wjd.v15.i10.2135","url":null,"abstract":"<p><strong>Background: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose co-transporter-2 inhibitors (SGLT-2I) are associated with significant cardiovascular benefit in type 2 diabetes (T2D). However, GLP-1RA or SGLT-2I alone may not improve some cardiovascular outcomes in patients with prior cardiovascular co-morbidities.</p><p><strong>Aim: </strong>To explore whether combining GLP-1RA and SGLT-2I can achieve additional benefit in preventing cardiovascular diseases in T2D.</p><p><strong>Methods: </strong>The systematic review was conducted according to PRISMA recommendations. The protocol was registered on PROSPERO (ID: 42022385007). A total of 107049 participants from eligible cardiovascular outcomes trials of GLP-1RA and SGLT-2I were included in network meta-regressions to estimate cardiovascular benefit of the combination treatment. Effect modification of prior myocardial infarction (MI) and heart failure (HF) was also explored to provide clinical insight as to when the combination treatment should be considered.</p><p><strong>Results: </strong>The estimated hazard ratios (HR)_{GLP-1RA/SGLT-2I} <i>_vs</i> _Placebo (0.75-0.98) and HR_Combination <i>_vs</i> _{GLP-1RA/SGLT-2I} (0.26-0.86) for primary and secondary cardiovascular outcomes suggested that the combination treatment may achieve additional cardiovascular benefit compared with GLP-1RA or SGLT-2I alone. In patients with prior MI or HF, the mono-therapies may not improve the overall cardiovascular outcomes, as the estimated HR_MI+/HF+ (0.57-1.52) suggested that GLP-1RA or SGLT-2I alone may be associated with lower risks of hospitalization for HF but not cardiovascular death.</p><p><strong>Conclusion: </strong>Considering its greater cardiovascular benefit in T2D, the combination treatment of GLP-1RA and SGLT-2I might be prioritized in patients with prior MI or HF, where the monotherapies may not provide sufficient cardiovascular protection.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"15 10","pages":"2135-2146"},"PeriodicalIF":4.2,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential mechanism of teneligliptin in the treatment of diabetic cardiomyopathy.","authors":"Jing Guo, Yi Cao, Qing-Yuan Wu, Lu-Sha Cen","doi":"10.4239/wjd.v15.i10.2002","DOIUrl":"10.4239/wjd.v15.i10.2002","url":null,"abstract":"<p><p>Diabetic cardiomyopathy (DCM), a complication of diabetes, poses a significant threat to public health, both its diagnosis and treatment presents challenges. Teneligliptin has promising applications and research implications in the treatment of diabetes mellitus. Zhang <i>et al</i> observed the therapeutic effect of teneligliptin on cardiac function in mice with DCM. They validated that teneligliptin's mechanism of action in treating DCM involves cardiomyocyte protection and inhibition of <i>NLRP3</i> inflammasome activity. Given that the <i>NLRP3</i> inflammasome plays a crucial role in the onset and progression of DCM, it presents a promising therapeutic target. Nevertheless, further clinical validation is required to ascertain the preventive and therapeutic efficacy of teneligliptin in DCM.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"15 10","pages":"2002-2005"},"PeriodicalIF":4.2,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota modulating therapy for diabetes mellitus should be individualized.","authors":"Jin Wang, Hong-Juan Wei, Rui-Feng Mao, Xin Chang","doi":"10.4239/wjd.v15.i10.2152","DOIUrl":"10.4239/wjd.v15.i10.2152","url":null,"abstract":"<p><p>In this editorial, we commented on two articles published online in August and September 2024 in the <i>World Journal of Diabetes</i>, which focused on modifying the gut microbiota (GM) to prevent or delay the progression of diabetes mellitus (DM) and DM-related complications. Numerous studies, many of which are animal studies, have indicated the potential role of GM in the pathogenesis of DM. However, the detailed causality and mechanisms between GM and DM have not been fully clarified. Although there have been some reports of a potential role of modifying the GM in treating DM, most lack long-term observations and are not mechanistic. Additionally, the GM and its role in DM might vary among individuals; therefore, GM-targeted interventions should be individualized to realize their therapeutic potential.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"15 10","pages":"2152-2156"},"PeriodicalIF":4.2,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy in type 1 diabetes: Novel pathway to the future ahead.","authors":"Sayantan Ray, Rajan Palui","doi":"10.4239/wjd.v15.i10.2022","DOIUrl":"10.4239/wjd.v15.i10.2022","url":null,"abstract":"<p><p>Since the discovery of insulin over 100 years ago, the focus of research in the management of type 1 diabetes (T1D) has centered around glycemic control and management of complications rather than the prevention of autoimmune destruction of pancreatic β cells. Fortunately, in recent years, there has been significant advancement in immune-targeted pharmacotherapy to halt the natural progression of T1D. The immune-targeted intervention aims to alter the underlying pathogenesis of T1D by targeting different aspects of the immune system. The immunotherapy can either antagonize the immune mediators like T cells, B cells or cytokines (antibody-based therapy), or reinduce self-tolerance to pancreatic β cells (antigen-based therapy) or stem-cell treatment. Recently, the US Food and Drug Administration approved the first immunotherapy teplizumab to be used only in stage 2 of T1D. However, the window of opportunity to practically implement this approved molecule in the selected target population is limited. In this Editorial, we briefly discuss the various promising recent developments in the field of immunotherapy research in T1D. However, further studies of these newer therapeutic agents are needed to explore their true potential for prevention or cure of T1D.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"15 10","pages":"2022-2035"},"PeriodicalIF":4.2,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes pathway in diabetes and its complications.","authors":"Ming-Wei Fan, Jin-Lan Tian, Tan Chen, Can Zhang, Xin-Ru Liu, Zi-Jian Zhao, Shu-Hui Zhang, Yan Chen","doi":"10.4239/wjd.v15.i10.2041","DOIUrl":"10.4239/wjd.v15.i10.2041","url":null,"abstract":"<p><p>Diabetes mellitus (DM) is one of the major causes of mortality worldwide, with inflammation being an important factor in its onset and development. This review summarizes the specific mechanisms of the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway in mediating inflammatory responses. Furthermore, it comprehensively presents related research progress and the subsequent involvement of this pathway in the pathogenesis of early-stage DM, diabetic gastroenteropathy, diabetic cardiomyopathy, non-alcoholic fatty liver disease, and other complications. Additionally, the role of cGAS-STING in autonomic dysfunction and intestinal dysregulation, which can lead to digestive complications, has been discussed. Altogether, this study provides a comprehensive analysis of the research advances regarding the cGAS-STING pathway-targeted therapeutic agents and the prospects for their application in the precision treatment of DM.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"15 10","pages":"2041-2057"},"PeriodicalIF":4.2,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical or medical treatment of obesity-associated type 2 diabetes-an increasing clinical conundrum.","authors":"Ryan J Jalleh, Karen L Jones, Md Shahidul Islam, Lu Cai, Michael Horowitz","doi":"10.4239/wjd.v15.i10.2036","DOIUrl":"10.4239/wjd.v15.i10.2036","url":null,"abstract":"<p><p>In this editorial, we comment on the article by He <i>et al</i>, specifically in relation to the efficacy of bariatric surgery <i>vs</i> glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy in the management of type 2 diabetes (T2D) associated with obesity. Bariatric surgery has now also been shown to be safe and effective in pre-teens and teenagers with obesity and T2D, but information on newer GLP-1RAs in these groups is predictably limited. In older individuals (age > 65 years), both bariatric surgery and GLP-1RA therapy improve cardiovascular outcomes. Bariatric surgery is not infrequently associated with post-operative postprandial hypoglycemia, which is not the case with GLP-1RAs and, paradoxically, there is evidence that GLP-1RAs may reduce both the frequency and severity of postprandial hypoglycemia. Comparative trials of the long-term efficacy of bariatric surgery and GLP-1RAs are indicated.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"15 10","pages":"2036-2040"},"PeriodicalIF":4.2,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of cuproptosis on acute kidney injury after cardiopulmonary bypass in diabetic patients.","authors":"Xi-Jin Deng, Yi-Nan Wang, Chuan-Bao Lv, Zhong-Zhi Qiu, Ling-Xin Zhu, Jing-Hui Shi, Si-Ri-Gu-Leng Sana","doi":"10.4239/wjd.v15.i10.2123","DOIUrl":"10.4239/wjd.v15.i10.2123","url":null,"abstract":"<p><strong>Background: </strong>Cardiopulmonary bypass (CPB) is a common procedure in cardiac surgery. CPB is a high-risk factor for acute kidney injury (AKI), and diabetes is also such a factor. Diabetes can lead to copper overload. It is currently unclear whether AKI after CPB in diabetic patients is related to copper overload.</p><p><strong>Aim: </strong>To explore whether the occurrence of CPB-AKI in diabetic patients is associated with cuproptosis.</p><p><strong>Methods: </strong>Blood and urine were collected from clinical diabetic and non-diabetic patients before and after CPB. Levels of copper ion, lactate, glucose, heat shock protein-70 (HSP-70), and dihydrolipoamide dehydrogenase (DLAT) were determined. A diabetic rat model was established and CPB was performed. The rats were assessed for the development of CPB-AKI, and for the association of AKI with cuproptosis by detecting copper levels, iron-sulfur cluster proteins and observation of mitochondrial structure by electron microscopy.</p><p><strong>Results: </strong>CPB resulted in elevations of copper, lactate, HSP-70 and DLAT in blood and urine in both diabetic and non-diabetic patients. CPB was associated with pathologic and mitochondrial damage in the kidneys of diabetic rats. Cuproptosis-related proteins also appeared to be significantly reduced.</p><p><strong>Conclusion: </strong>CPB-AKI is associated with cuproptosis. Diabetes mellitus is an important factor aggravating CPB-AKI and cuproptosis.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"15 10","pages":"2123-2134"},"PeriodicalIF":4.2,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}